Agree, I was also going to chime in to say that the sweet spot...

Agree, I was also going to chime in to say that the sweet spot for BP takeover is post phase 2.

The only reason for Neuren to progress ph 3 is because we can, as it shows we’re not completely reliant on BP if they don’t put forward a value offer at ph2.

Our fourth lagging trial is potentially a thorn in our side so we don’t want to be seen sitting on our hands after ph2 for the 3 indications we’ll have in the kitty, awaiting an offer.

We need to show, and we are, that we won’t be sold short and we can actually go all the way if need be.

I let son ally don’t see this occurring if we get get good Angleman results - it’ll be game on…